scholarly journals An Inter-Species Translation Model Implicates Integrin Signaling in Infliximab-Resistant Colonic Crohn’s Disease

2019 ◽  
Author(s):  
Douglas. K. Brubaker ◽  
Manu. P. Kumar ◽  
Paige. N. Vega ◽  
Austin. N. Southard-Smith ◽  
Alan. J. Simmons ◽  
...  

AbstractAnti-TNF therapy resistance is a major clinical challenge in Crohn’s Disease (CD), partly due to insufficient understanding of disease-site, protein-level mechanisms of CD and anti-TNF treatment resistance. Although some proteomics data from CD mouse models exists, data type and phenotype discrepancies contribute to confounding attempts to translate between preclinical animal models of disease and human clinical cohorts. To meet this important challenge, we develop and demonstrate here an approach called Translatable Components Regression (TransComp-R) to overcome inter-species and trans-omic discrepancies between CD mouse models and human subjects. TransComp-R combines CD mouse model proteomic data with patient pre-treatment transcriptomic data to identify molecular features discernable in the mouse data predictive of patient response to anti-TNF therapy. Interrogating the TransComp-R models predominantly revealed upregulated integrin pathway signaling via collagen-binding integrin ITGA1 in anti-TNF resistant colonic CD (cCD) patients. Toward validation, we performed single-cell RNA sequencing on biopsies from a cCD patient and analyzed publicly available immune cell proteomics data to characterize the immune and intestinal cell types contributing to anti-TNF resistance. We found that ITGA1 is indeed expressed in colonic T-cell populations and that interactions between collagen-binding integrins on T-cells and colonic cell types expressing secreted collagens are associated with anti-TNF therapy resistance. Biologically, TransComp-R linked previously disparate observations about collagen and ITGA1 signaling to a potential therapeutic avenue for overcoming anti-TNF therapy resistance in cCD. Methodologically, TransComp-R provides a flexible, generalizable framework for addressing inter-species, inter-omic, and inter-phenotypic discrepancies between animal models and patients to deliver translationally relevant biological insights.One Sentence SummaryBrubaker et al. implicate dysregulated collagen-binding integrin signaling in resistance to anti-TNF therapy in Crohn’s Disease by developing a mouse-proteomic to human-transcriptomic translation model and confirm the associated inter-cellular signaling network using single-cell RNA sequencing.

2020 ◽  
Vol 13 (643) ◽  
pp. eaay3258
Author(s):  
Douglas K. Brubaker ◽  
Manu P. Kumar ◽  
Evan L. Chiswick ◽  
Cecil Gregg ◽  
Alina Starchenko ◽  
...  

Anti–tumor necrosis factor (anti-TNF) therapy resistance is a major clinical challenge in inflammatory bowel disease (IBD), due, in part, to insufficient understanding of disease-site, protein-level mechanisms. Although proteomics data from IBD mouse models exist, data and phenotype discrepancies contribute to confounding translation from preclinical animal models of disease to clinical cohorts. We developed an approach called translatable components regression (TransComp-R) to overcome interspecies and trans-omic discrepancies between mouse models and human subjects. TransComp-R combines mouse proteomic data with patient pretreatment transcriptomic data to identify molecular features discernable in the mouse data that are predictive of patient response to therapy. Interrogating the TransComp-R models revealed activated integrin pathway signaling in patients with anti–TNF-resistant colonic Crohn’s disease (cCD) and ulcerative colitis (UC). As a step toward validation, we performed single-cell RNA sequencing (scRNA-seq) on biopsies from a patient with cCD and analyzed publicly available immune cell proteomics data to characterize the immune and intestinal cell types contributing to anti-TNF resistance. We found that ITGA1 was expressed in T cells and that interactions between these cells and intestinal cell types were associated with resistance to anti-TNF therapy. We experimentally showed that the α1 integrin subunit mediated the effectiveness of anti-TNF therapy in human immune cells. Thus, TransComp-R identified an integrin signaling mechanism with potential therapeutic implications for overcoming anti-TNF therapy resistance. We suggest that TransComp-R is a generalizable framework for addressing species, molecular, and phenotypic discrepancies between model systems and patients to translationally deliver relevant biological insights.


PLoS ONE ◽  
2021 ◽  
Vol 16 (7) ◽  
pp. e0254194
Author(s):  
Hong-Tae Park ◽  
Woo Bin Park ◽  
Suji Kim ◽  
Jong-Sung Lim ◽  
Gyoungju Nah ◽  
...  

Mycobacterium avium subsp. paratuberculosis (MAP) is a causative agent of Johne’s disease, which is a chronic and debilitating disease in ruminants. MAP is also considered to be a possible cause of Crohn’s disease in humans. However, few studies have focused on the interactions between MAP and human macrophages to elucidate the pathogenesis of Crohn’s disease. We sought to determine the initial responses of human THP-1 cells against MAP infection using single-cell RNA-seq analysis. Clustering analysis showed that THP-1 cells were divided into seven different clusters in response to phorbol-12-myristate-13-acetate (PMA) treatment. The characteristics of each cluster were investigated by identifying cluster-specific marker genes. From the results, we found that classically differentiated cells express CD14, CD36, and TLR2, and that this cell type showed the most active responses against MAP infection. The responses included the expression of proinflammatory cytokines and chemokines such as CCL4, CCL3, IL1B, IL8, and CCL20. In addition, the Mreg cell type, a novel cell type differentiated from THP-1 cells, was discovered. Thus, it is suggested that different cell types arise even when the same cell line is treated under the same conditions. Overall, analyzing gene expression patterns via scRNA-seq classification allows a more detailed observation of the response to infection by each cell type.


2019 ◽  
Vol 156 (3) ◽  
pp. 812-815.e22 ◽  
Author(s):  
Werna T. Uniken Venema ◽  
Michiel D. Voskuil ◽  
Arnau Vich Vila ◽  
Gerben van der Vries ◽  
Bernadien H. Jansen ◽  
...  

Author(s):  
Rasa Elmentaite ◽  
Alexander Ross ◽  
Kylie R. James ◽  
Daniel Ortmann ◽  
Tomas Gomes ◽  
...  

SummaryHuman gut development requires the orchestrated interaction of various differentiating cell types. Here we generate an in-depth single-cell map of the developing human intestine at 6–10 weeks post-conception, a period marked by crypt-villus formation. Our analysis reveals the transcriptional profile of cycling epithelial precursor cells, which are distinct from LGR5-expressing cells. We use computational analyses to show that these cells contribute to differentiated cell subsets directly and indirectly via the generation of LGR5-expressing stem cells and receive signals from the surrounding mesenchymal cells. Furthermore, we draw parallels between the transcriptomes of ex vivo tissues and in vitro fetal organoids, revealing the maturation of organoid cultures in a dish. Lastly, we compare scRNAseq profiles from paediatric Crohn’s disease epithelium alongside matched healthy controls to reveal disease associated changes in epithelial composition. Contrasting these with the fetal profiles reveals re-activation of fetal transcription factors in Crohn’s disease epithelium. Our study provides a unique resource, available at www.gutcellatlas.org, and underscores the importance of unravelling fetal development in understanding disease.


2018 ◽  
Vol 154 (6) ◽  
pp. S-189 ◽  
Author(s):  
Werna T. Uniken Venema ◽  
Michiel D. Voskuil ◽  
Arnau Vich Vila ◽  
Daniel B. Graham ◽  
Rinse K. Weersma ◽  
...  

2019 ◽  
Vol 157 (1) ◽  
pp. 265-266
Author(s):  
Min Du ◽  
Rui Dong ◽  
Shan Zheng

2018 ◽  
Vol 12 (supplement_1) ◽  
pp. S019-S020
Author(s):  
E Festen ◽  
R Weersma ◽  
W T Uniken Venema ◽  
M D Voskuil ◽  
D Graham

2021 ◽  
Vol 3 (1) ◽  
Author(s):  
Nadin Kamal Hawwash

Mesenchymal stem cells (MSCs) are self-renewing stromal cells that possess a multipotent differentiation capacity as they can differentiate into numerous cell types such as adipose, bone and cartilage cells. MSCs have generated considerable interest for their remarkable tissue-reparative and immunomodulatory properties whereby MSCs can develop into functional cells at the injury site and control the body’s response to tissue damage respectively. Consequently, MSCs have vast therapeutic potential in treating Crohn’s disease (CD) which is a lifelong inflammatory bowel disease where tissue damage to a section of the gastrointestinaltract occurs. The review aims to discuss the properties of MSCs and explore their potential application in treating CD. This review highlights the tissue-reparative properties of MSCs and specifically focuses on the immunomodulatory properties of MSCs. Results from clinical trials regarding the efficacy and safety of MSCs have been promising, proving that MSCs could potentially be used to treat CD.


Sign in / Sign up

Export Citation Format

Share Document